^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

MET positive

i
Other names: DFNB97, AUTS9, RCCP2, C-Met, HGFR, HGF Receptor, Met Proto-Oncogene, HGF/SF Receptor, Proto-Oncogene C-Met, Scatter Factor Receptor, Tyrosine-Protein Kinase Met, Hepatocyte Growth Factor Receptor, MET, MET Proto-Oncogene, Receptor Tyrosine Kinase
Entrez ID:
27d
MET overexpression correlated with prognosis of EGFR-mutant treatment‑naïve advanced lung adenocarcinoma: a real‑world retrospective study. (PubMed, Clin Transl Oncol)
MET positive expression was an independent predictor of poor outcomes in untreated EGFR L858R mutation advanced LUAD patients treated with first-line EGFR-TKI monotherapy.
Retrospective data • Journal • Real-world evidence • Real-world • Metastases
|
EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR expression • MET overexpression • EGFR L861Q • EGFR S768I • MET expression • MET positive • EGFR G719A • EGFR G719C
1m
Comparison of Tepotinib, Paclitaxel, or Ramucirumab Efficacy According to the Copy Number or Phosphorylation Status of the MET Gene: Doublet Treatment versus Single Agent Treatment. (PubMed, Int J Mol Sci)
These in vitro findings suggest that compared with ramucirumab-plus-paclitaxel, tepotinib-plus-paclitaxel better inhibits the growth of c-MET-positive GC cells, cells lacking MET amplification but containing phosphorylated MET, and cells containing MET mutations. Clinical studies are required to confirm the therapeutic effects of these regimens.
Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET amplification • MET exon 14 mutation • MET mutation • MET positive
|
paclitaxel • Cyramza (ramucirumab) • Tepmetko (tepotinib)
2ms
c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive/HER2-negative metastatic breast cancer. (PubMed, Breast Cancer Res)
Monitoring c-MET+ CTC, rather than assessing c-MET expression in the primary BC site, could provide valuable information for predicting disease progression, as c-MET expression can change during treatment. The c-MET+ CTC count and cfDNA concentration could provide complementary information on disease progression in HR+ /HER2- mBC, highlighting the importance of integrated liquid biopsy.
Journal • Circulating tumor cells • Tumor cell • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MET (MET proto-oncogene, receptor tyrosine kinase) • EPCAM (Epithelial cell adhesion molecule)
|
HER-2 positive • HR positive • HER-2 negative • PIK3CA mutation • MET overexpression • ER mutation • MET expression • ESR1 mutation • MET positive • HR positive + HER-2 negative • PTEN mutation + HR positive
4ms
[11C] Methionine PET in Diagnosing Pediatric Low-grade Gliomas (RSNA 2023)
Both quantitative and qualitative MET-PET have high sensitivity in diagnosing pLGG, both newly diagnosed and previously treated. *Clinical Relevance/Application: With its high sensitivity, MET-PET can be used to complement equivocal MRI.
Clinical
|
MET positive
4ms
Validation of a Fluorescent MET-Targeting Probe for Assisting Biopsy in OPMDs (RSNA 2023)
Compared to standard biopsy, the use of cMBP-ICG in conjunction with NIRFI may improve the detection of IHD. *Clinical Relevance/Application: The NIRF probe cMBP-ICG and NIRF imaging system may provide a non-invasive method for biopsy sampling assistance, potentially changing the clinical protocol for OPMDs, and improving the early diagnosis rate of OSCC.
Biopsy
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET expression • MET positive
4ms
Clinical • Real-world evidence • Real-world
|
BRAF (B-raf proto-oncogene)
|
MET positive
5ms
c-Met immunohistochemistry as reflex test at diagnosis for non-small cell lung cancer: a real-world experience from a monocentric case series. (PubMed, J Clin Pathol)
Systematic c-Met testing in daily routine for NSCLC patients is feasible, highlighting a potential correlation with clinicopathological and molecular features.
Journal • Real-world evidence • PD(L)-1 Biomarker • IO biomarker • Real-world • Reflex
|
PD-L1 (Programmed death ligand 1) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
PD-L1 expression • PD-L1 overexpression • MET overexpression • MET expression • MET positive
5ms
Radiomics Based on Contrast-Enhanced CT for Recognizing c-Met-Positive Hepatocellular Carcinoma: a Noninvasive Approach to Predict the Outcome of Sorafenib Resistance. (PubMed, Mol Imaging Biol)
A multivariate model acquired from three phases (AP, VP and DP) of enhanced CT, HBV-DNA and γ glutamyl transpeptidase isoenzyme II (GGT-II) could be considered a satisfactory preoperative marker of the expression of c-Met in patients with HCC. This approach may help in overcoming sorafenib resistance in advanced HCC.
Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET expression • MET positive
|
sorafenib
5ms
New P3 trial • Metastases
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
EGFR mutation • EGFR L858R • EGFR T790M • MET positive
|
cisplatin • carboplatin • pemetrexed • Ameile (aumolertinib) • HS-10241
5ms
Enrollment closed
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
KRAS G12C • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • ALK rearrangement • EGFR L861Q • ROS1 positive • KRAS G12 • EGFR exon 20 mutation • MET positive • EGFR negative
|
Opdivo (nivolumab) • gemcitabine • docetaxel • Cabometyx (cabozantinib tablet) • albumin-bound paclitaxel • Cyramza (ramucirumab) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)
6ms
Trial suspension
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
KRAS G12C • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • ALK rearrangement • EGFR L861Q • ROS1 positive • KRAS G12 • EGFR exon 20 mutation • MET positive • EGFR negative
|
Opdivo (nivolumab) • gemcitabine • docetaxel • Cabometyx (cabozantinib tablet) • albumin-bound paclitaxel • Cyramza (ramucirumab) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)
7ms
The prognostic power of [C]methionine PET in IDH-wildtype diffuse gliomas with lower-grade histological features: venturing beyond WHO classification. (PubMed, J Neurooncol)
MET PET is useful for the prognostic stratification of patients with IDH-wt glial neoplasms with histological LGGs features. Considering their huge biological heterogeneity, the combination of MET PET and molecular analyses may help to improve the prognostic accuracy in these diffuse gliomas subset and influence therapeutic choices accordingly.
Journal
|
MET positive • IDH wild-type
8ms
Albumin-Based Cyanine Crizotinib Conjugate Nanoparticles for NIR-II Imaging-Guided Synergistic Chemophototherapy. (PubMed, ACS Appl Mater Interfaces)
Under 808 nm laser irradiation, Crizotinib-IR808@BSA NPs exhibited synergistic chemophototherapy effects on tumors. In conclusion, this innovative imaging-mediated multifunctional combination therapy strategy with good c-Met targeting ability may provide a new approach for colorectal cancer treatment.
Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET positive
|
Xalkori (crizotinib)
11ms
Analytical Performance of a Highly Sensitive System to Detect Gene Variants Using Next-Generation Sequencing for Lung Cancer Companion Diagnostics. (PubMed, Diagnostics (Basel))
The identity rates were as follows: EGFR positive, 100% (95% confidence interval, 95.5-100); EGFR negative, 90.9 (82.2-96.3); BRAF positive, 100 (59.0-100); BRAF negative, 100 (94.9-100); KRAS G12C positive, 100 (92.7-100); KRAS G12C negative, 100 (93.0-100); ALK positive, 96.7 (83.8-99.9); ALK negative, 98.4 (97.2-99.2); ROS1 positive, 100 (66.4-100); ROS1 negative, 99.0 (94.6-100); MET positive, 98.0 (89.0-99.9); MET negative 100 (92.8-100); RET positive, 93.8 (69.8-100); RET negative, 100 (94.9-100). The analytical performance showed that the panel could handle various types of biopsy samples obtained by routine clinical practice without requiring strict pathological monitoring, as in the case of conventional NGS panels.
Journal • Next-generation sequencing • Companion diagnostic
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
BRAF V600E • KRAS G12C • BRAF V600 • EGFR L858R • EGFR exon 19 deletion • ALK positive • EGFR T790M • ROS1 positive • KRAS G12 • EGFR positive • MET positive • EGFR negative • ALK negative • KRAS deletion • RET positive
11ms
Savolitinib versus crizotinib for treating MET positive non-small cell lung cancer. (PubMed, Thorac Cancer)
In METex14 skipping NSCLC patients, the efficacy of savolitinib and crizotinib did not show significant difference. In MET amplification patients, savolitinib showed better efficacy than crizotinib.
Retrospective data • Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET amplification • MET positive
|
Xalkori (crizotinib) • Orpathys (savolitinib)
1year
Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer (clinicaltrials.gov)
P2, N=117, Recruiting, National Cancer Institute (NCI) | Trial completion date: May 2023 --> Jun 2024 | Trial primary completion date: May 2023 --> Jun 2024
Trial completion date • Trial primary completion date
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
KRAS G12C • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • ALK rearrangement • EGFR L861Q • ROS1 positive • KRAS G12 • EGFR exon 20 mutation • MET positive • EGFR negative
|
Opdivo (nivolumab) • gemcitabine • docetaxel • Cabometyx (cabozantinib tablet) • albumin-bound paclitaxel • Cyramza (ramucirumab) • Cometriq (cabozantinib capsule)
1year
First in human dose-escalation trial with the c-MET targeting antibody-drug conjugate BYON3521 (AACR 2023)
To date, BYON3521 is well-tolerated with no DLTs at the investigated dose levels. Patient enrollment is ongoing and updated safety, efficacy and pharmacokinetic data will be presented. After the dose-escalation phase the trial will continue with expanded cohorts of patients with specific c-MET expressing cancer types.
P1 data
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET amplification • MET exon 14 mutation • MET mutation • MET expression • MET positive
|
BYON3521
1year
A Study of RC108-ADC in Subjects With Advanced Digestive System Malignant Tumor (clinicaltrials.gov)
P2, N=240, Recruiting, RemeGen Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET positive
|
RC108
1year
MET gene copy number heterogeneity in non-small cell lung cancer patients resistant to EGFR-TKIs (ELCC 2023)
In technology, FISH showed advantages in detection of MET GCN as compared with NGS. Collectively, these results may provide a guiding role in the accurate detection of MET GCN and subsequent treatments.
Clinical
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET amplification • MET positive
1year
Engineering c-Met-CAR NK-92 cells as a promising therapeutic candidate for lung adenocarcinoma. (PubMed, Pharmacol Res)
Furthermore, CCN4 cells also exerted the prominent tumor-inhibitory effect on xenograft tumor growth. Collectively, this study suggests that DAP10 is a potent stimulator in CAR structure for NK cell activation, and CCN4-based immunotherapy may represent a promising strategy for the treatment of c-Met-positive LUAD.
Journal • IO biomarker
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET expression • MET positive • MET-H
1year
Concordance of MET Amplification between Fluorescence In Situ Hybridization (FISH) and Next-Generation Sequencing (NGS) in Non-Small Cell Lung Carcinoma (NSCLC) (USCAP 2023)
Based on our results, most samples demonstrate high concordance between FISH and NGS, especially among the FISH-positive group. With a high NPV, NGS is a viable screening method for MET amplification. Multiple factors can contribute to discrepant results between NGS and FISH, including assay-related factors such as individual cells analyzed vs collective tumor populations and local vs global genomic changes.
Next-generation sequencing • Discordant
|
EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET amplification • MET exon 14 mutation • MET mutation • MET positive
over1year
Dynamic changes of the EMT spectrum between circulating tumor cells and the tumor microenvironment in human papillomavirus-positive head and neck squamous cell carcinoma. (PubMed, Oral Oncol)
Our results provide novel insights into the EMT-MET spectrum of CTCs and may contribute to the development of prognostic biomarkers for HPV-positive HNSCC.
Journal • Circulating tumor cells • IO biomarker • Tumor cell
|
EGFR (Epidermal growth factor receptor) • CD38 (CD38 Molecule) • CDH1 (Cadherin 1) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • EPCAM (Epithelial cell adhesion molecule) • CDH2 (Cadherin 2) • TWIST1 (Twist Family BHLH Transcription Factor 1) • SNAI1 (Snail Family Transcriptional Repressor 1) • SNAI2 (Snail Family Transcriptional Repressor 2) • ZEB1 (Zinc Finger E-box Binding Homeobox 1) • ZEB2 (Zinc Finger E-Box Binding Homeobox 2)
|
MET positive • CDH1 expression • EPCAM expression • ZEB1 expression
over1year
MET gene alterations predict poor survival following chemotherapy in patients with advanced cancer. (PubMed, Pathol Oncol Res)
Thus, MET aberration was determined to be a factor of response to chemotherapy. Approximately 2.1% and 0.4% of patients with advanced solid tumors demonstrated MET gene amplification and fusion, respectively, and displayed a worse response to chemotherapy and significantly shorter OS and PFS than those without MET gene amplification or fusion.
Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • MET (MET proto-oncogene, receptor tyrosine kinase) • MSI (Microsatellite instability) • CAV1 (Caveolin 1) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • PCM1 (Pericentriolar Material 1) • CAPZA2 (Capping Actin Protein Of Muscle Z-Line Subunit Alpha 2)
|
TMB-H • MET amplification • MET mutation • MET positive • MET fusion
|
PD-L1 IHC 22C3 pharmDx
over1year
New P2 trial • Metastases
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET positive
|
RC108
over1year
Design and Rationale for a Phase II, Randomized, Open-Label, Two-Cohort Multicenter Interventional Study of Osimertinib with or Without Savolitinib in De Novo MET Aberrant, EGFR-Mutant Patients with Advanced Non-Small-Cell Lung Cancer: The FLOWERS Trial. (PubMed, Clin Lung Cancer)
The results of the study will provide better perspectives on the efficacy and safety of EGFR-TKI plus MET-TKI combination therapy (osimertinib plus savolitinib) in patients with de novo MET-amplified/over-expressed, EGFR-mutant positive, treatment naïve, advanced NSCLC and offer a meaningful guidance in clinical practice (NCT05163249).
P2 data • Journal
|
EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
EGFR mutation • MET amplification • EGFR expression • EGFR overexpression • MET overexpression • MET mutation • EGFR positive • MET positive
|
Tagrisso (osimertinib) • Orpathys (savolitinib)
over1year
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer. (PubMed, J Clin Oncol)
Teliso-V plus erlotinib showed encouraging antitumor activity and acceptable toxicity in EGFR TKI-pretreated patients with EGFR-M+, c-Met+ NSCLC.
P1 data • Journal • Combination therapy
|
EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
EGFR mutation • EGFR T790M • MET overexpression • MET expression • MET positive • MET-H
|
erlotinib • telisotuzumab vedotin (ABBV-399)
over1year
EFFICACY AND SAFETY OF NABPACLITAXEL PLUS ATEZOLIZUMAB AS FIRST-LINE TREATMENT OF PD-L1- POSITIVE METASTATIC TRIPLE-NEGATIVE BREAST CANCER (TNBC): RESULTS OF THE MULTICENTER, REAL-WORD ‘ANASTASE’ STUDY (AIOM 2022)
PD-L1-positive metastatic TNBC pts treated with first-line nab-paclitaxel plus atezolizumab substan- tially derived, in a ‘real-word’ context, similar PFS and ORR than those reported in the IM130 study, without unexpected adverse events.
Clinical
|
PD-L1 (Programmed death ligand 1) • BRCA (Breast cancer early onset)
|
PD-L1 expression • MET positive
|
Tecentriq (atezolizumab) • albumin-bound paclitaxel
over1year
Ultra-fast gene fusion assessment as a reflex testing in daily clinical practice for advanced non-small cell lung cancer patients (ECP 2022)
Ultra-fast gene fusion evaluation using NGS or RT-PCR approaches should be developed as a reflex testing for NS-NSCLC at diagnosis in order to treat these patients according to the international recommendations and guidelines.
Clinical
|
ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
|
ROS1 positive • MET positive
|
Oncomine Precision Assay
almost2years
Ultra-Fast Gene Fusion Assessment as a Reflex Testing in Daily Clinical Practice for Advanced Non-small Cell Lung Cancer Patients (IASLC-WCLC 2022)
Ultra-fast gene fusion evaluation using NGS or RT-PCR approaches should be developed as a reflex testing for NS-NSCLC at diagnosis in order to treat these patients according to the international recommendations and guidelines.
Clinical
|
ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
|
ROS1 positive • MET positive
|
Idylla™ GeneFusion Assay • Oncomine Precision Assay
almost2years
New P1 trial • Combination therapy
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET positive • EGFR T790M negative
|
Ameile (aumolertinib) • HS-10241
almost2years
PIK3CA Mutation as Potential Poor Prognostic Marker in Asian Female Breast Cancer Patients Who Received Adjuvant Chemotherapy. (PubMed, Curr Oncol)
PIK3CA mutation together with c-Met or dMMR/MSI status might be relevant to poor prognosis in BC subsets, especially in Asian women.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MET (MET proto-oncogene, receptor tyrosine kinase) • MSI (Microsatellite instability)
|
PD-L1 expression • MSI-H/dMMR • PIK3CA mutation • MET mutation • MET expression • MET positive • PIK3CA wild-type
almost2years
GeoMETry-III: Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation (clinicaltrials.gov)
P3, N=90, Recruiting, Novartis Pharmaceuticals | Trial completion date: Oct 2024 --> Apr 2025 | Trial primary completion date: Jul 2023 --> Apr 2025
Trial completion date • Trial primary completion date
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
EGFR mutation • ALK rearrangement • EGFR wild-type • MET mutation • MET positive
|
docetaxel • Tabrecta (capmatinib)
almost2years
Cytology-histology correlation of myoepithelial tumors harboring EWSR1-POU5F1 fusions: A report of two cases. (PubMed, Diagn Cytopathol)
The cytomorphology of these tumors has not been well characterized. Reported here are the cytomorphologic features of two cases of EWSR1-POUF1-positive MET with histology correlation.
Journal
|
EWSR1 (EWS RNA Binding Protein 1) • POU5F1 (POU Class 5 Homeobox 1)
|
MET positive • EWSR1-POU5F1 fusion
almost2years
Prevalence of MET aberration using next generation sequencing in oncology clinic: A real-world experience. (ASCO 2022)
Based on our comprehensive NGS survey focused on MET aberration, we identified approximately 2.1% MET amplification and 0.4% MET fusion in patients with metastatic solid tumors. They showed worse response after chemotherapy and shorter OS and PFS.
Real-world evidence • Clinical • PD(L)-1 Biomarker • IO biomarker • Next-generation sequencing
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • MET (MET proto-oncogene, receptor tyrosine kinase) • CAV1 (Caveolin 1) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • PCM1 (Pericentriolar Material 1)
|
TMB-H • MET amplification • MET positive • MET fusion
|
PD-L1 IHC 22C3 pharmDx • TruSight Oncology 500 Assay
almost2years
c-Met specific CAR-T cells as a targeted therapy for non-small cell lung cancer cell A549. (PubMed, Bioengineered)
Taken together, we provided useful method to generate c-Met CAR- T cells, which exhibit enhanced cytotoxicity against NSCLC cells in vitro and in vivo. Thus, providing a new therapeutic avenue for treating NSCLC clinically.Highlights (1) c-Met CAR-T capable of stably expressing c-Met CARs were constructed.(2) c-Met CAR-T have strong anti-tumor ability and proliferation ability in vitro.(3) c-Met CAR-T can effectively inhibit the growth of A549 cells subcutaneous xenografts.
Journal • CAR T-Cell Therapy
|
MET (MET proto-oncogene, receptor tyrosine kinase) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2)
|
MET expression • MET positive
almost2years
c-Met-targeted chimeric antigen receptor T cells inhibit hepatocellular carcinoma cells in vitro and in vivo. (PubMed, J Biomed Res)
Moreover, c-Met-28-137-3ζ CAR-T cells eradicated HCC more effectively in xenograft tumor models compared with the control groups. This study suggests that 3 -generation c-Met CAR-T cells are more effective in inhibiting c-Met-positive HCC cells than 2 -generation c-Met CAR-T cells, thereby providing a promising therapeutic intervention for c-Met-positive HCC.
Preclinical • Journal • CAR T-Cell Therapy
|
MET (MET proto-oncogene, receptor tyrosine kinase) • IFNG (Interferon, gamma) • IL2 (Interleukin 2) • TNFRSF9 (TNF Receptor Superfamily Member 9)
|
MET overexpression • MET expression • MET positive • MET-H
almost2years
New P1 trial
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET amplification • MET exon 14 mutation • MET mutation • MET positive
|
BYON3521
almost2years
First In-Human Results of 68Ga-EMP-100 PET for Imaging c-MET Expression in Renal Cell Carcinoma (AUA 2022)
Conclusions : 68Ga-EMP-100 which targets c-MET expression shows increased uptake in mRCC patients with high inter- and intraindividual differences. Our pilot study shows that 68Ga-EMP-100 could be a promising molecular imaging tool for mRCC patients undergoing tyrosine kinase inhibitor therapies.
P1 data
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET expression • MET positive
|
Cabometyx (cabozantinib tablet)